| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11219597 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10864219 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9056057 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9532955 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10058511 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10646437 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US11642317 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10688045 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9393213 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9737491 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9827191 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
Inveltys is owned by Alcon Labs Inc.
Inveltys contains Loteprednol Etabonate.
Inveltys has a total of 11 drug patents out of which 0 drug patents have expired.
Inveltys was authorised for market use on 22 August, 2018.
Inveltys is available in suspension/drops;ophthalmic dosage forms.
Inveltys can be used as a method for delivering a composition to a mucus membrane, a method of treating postoperative inflammation following ocular surgery, a method for treating inflammation and/or other disorders in an eye of a patient, a method for delivering a pharmaceutical agent across a mucosal barrier, a method for treating ocular inflammation.
The generics of Inveltys are possible to be released after 03 May, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 22, 2021 |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 22 August, 2018
Treatment: A method of treating postoperative inflammation following ocular surgery; A method for treating ocular inflammation; A method for delivering a composition to a mucus membrane; A method for delivering ...
Dosage: SUSPENSION/DROPS;OPHTHALMIC
INVELTYS family patents
